...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Need An Explanation
Some good points made here. One question I have, which I emailed Zenith about last night, is does this latest financing dilute Zenith Capital Corp. I suspect it does but one of the reasons for the reorg was supposedly to prevent dilution of ownership of RVX royalty preferred shares. Since this financing was done after the vote on the reorg but prior to the execution of the split it seems like a bit of a grey area. I will share my answer if I get one.
Share
New Message
Please login to post a reply